奥妥珠单抗、伊布替尼与维奈克拉联合方案治疗初治及复发或难治性慢性淋巴细胞白血病的II期研究
这项II期研究评估奥妥珠单抗、伊布替尼与维奈克拉联合方案共14个周期,用于初治(n=25)及复发或难治(n=25)慢性淋巴细胞白血病患者,以确定疗效与安全性。主要终点为治疗结束2个月时血液和骨髓流式细胞术检测均无可检测微小残留病的完全缓解率,两组均为28%。中位随访期间仅1例进展、1例死亡,中位无进展生存和总生存均未达到。
要点
- 治疗结束2个月时,初治组和复发或难治组的完全缓解且微小残留病不可检测率均为28%。
- 治疗结束2个月时,初治组总缓解率为84%,复发或难治组为88%。
- 3或4级中性粒细胞减少发生率为66%,复发或难治队列事件更多,仅1次中性粒细胞减少性发热。
核心结论
- 奥妥珠单抗、伊布替尼与维奈克拉联合方案提供限时治疗,可实现深度缓解,目前正在合作组III期试验中研究。
研究设计与样本
- II期研究,评估奥妥珠单抗、伊布替尼与维奈克拉联合方案共14个周期,纳入初治(n=25)及复发或难治(n=25)慢性淋巴细胞白血病患者,以确定疗效与安全性。
主要发现
- 治疗结束2个月时,完全缓解且血液和骨髓流式细胞术检测均无可检测微小残留病的比例在初治组和复发或难治组均为28%。
关键数值与推荐
- 治疗结束2个月时,总缓解率初治组为84%、复发或难治组为88%;血液和骨髓均无可检测微小残留病者初治组为67%、复发或难治组为50%。
临床怎么用
- 原研究结论指出该联合方案提供限时治疗并可实现深度缓解,现正在合作组III期试验中研究。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy. PATIENTS AND METHODS: This phase II study tested a combination regimen of obinutuzumab, ibrutinib, and venetoclax for a total of 14 cycles in both patients with treatment-naïve (n = 25) and relapsed or refractory (n = 25) chronic lymphocytic leukemia to determine the response to therapy and safety. RESULTS: The primary end point was the rate of complete remission with undetectable minimal residual disease by flow cytometry in both the blood and bone marrow 2 months after completion of treatment, which was 28% in both groups. The overall response rate at that time was 84% in treatment-naïve patients and 88% in relapsed or refractory patients. At that time, 67% of treatment-naïve patients and 50% of relapsed or refractory patients had undetectable minimal residual disease in both the blood and marrow. At a median follow-up of 24.2 months in treatment-naïve patients and 21.5 months in relapsed or refractory patients, the median progression-free and overall survival times were not yet reached, with only 1 patient experiencing progression and 1 death. Neutropenia and thrombocytopenia were the most frequent adverse events, followed by hypertension. Grade 3 or 4 neutropenia was experienced by 66% of patients, with more events in the relapsed or refractory cohort. There was only 1 episode of neutropenic fever. A favorable impact on both perceived and objective cognitive performance during treatment was observed. CONCLUSION: The combination regimen of obinutuzumab, ibrutinib, and venetoclax offers time-limited treatment that results in deep remissions and is now being studied in phase III cooperative group trials.
引用
- Rogers KA, Huang Y, Ruppert AS, et al. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020. PMID: 32795224. doi:10.1200/JCO.20.00491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。